Angelo Nascimbene is a Cardiology physician affiliated with University of Houston. OpenAlex indexes 80 publications with 4,041 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6400 Fannin St Ste 2500
Houston, TX 770301537
Telephone
713-704-4300Provider last certified this registry record 27 Jan 2025.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year202510 payments
- Novo Nordisk IncProgram year202512 payments
- GE HEALTHCAREProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
71.6%Beta blocker12.1%Carvedilol62%Metoprolol Succinate30%Metoprolol Tartrate9%Part D<11 patientsStatin11.7%Atorvastatin Calcium64%Rosuvastatin Calcium36%Part D≥24 patients+ 9 more classes in this area
Metabolism & gastrointestinal
17.2%SGLT2 inhibitor9.9%Farxiga100%Part D≥19 patientsGLP-1 receptor agonist3.8%Ozempic100%Part D<11 patients+ 2 more classes in this area
Blood & clotting
11.2%Factor Xa inhibitor4.2%Eliquis100%Part D<11 patientsP2Y12 inhibitor3.8%Clopidogrel100%Part D≥13 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:
- Von Willebrand Factor Hyperactivity, Angiogenesis and LVAD-Induced Bleeding
University of Texas Hlth Sci Ctr Houston
FY2026$594,080R01HL163549 - Von Willebrand Factor Hyperactivity, Angiogenesis and LVAD-Induced Bleeding
University of Texas Hlth Sci Ctr Houston
FY2025$606,203R01HL163549 - Von Willebrand Factor Hyperactivity, Angiogenesis and LVAD-Induced Bleeding
University of Texas Hlth Sci Ctr Houston
FY2024$594,080R01HL163549
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Arthur Garson, MD
University of Houston
Shervin Assassi, MD
University of Houston
Pranav Loyalka, MD
University of Houston
Ertug Kovanci, MD
University of Houston
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”